TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. - Wikidata - awgldk - TriplyDB

TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

http://www.wikidata.org/entity/Q33604496

about

Physiologic characterization of type 2 diabetes-related loci Novel phenotypes of prediabetes?Recent advances in the molecular genetics of type 2 diabetes mellitus The alliance of mesenchymal stem cells, bone, and diabetes Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application.Effects of genetic susceptibility for type 2 diabetes on the evolution of glucose homeostasis traits before and after diabetes diagnosis: data from the D.E.S.I.R. Study.Diabetes mellitus: The epidemic of the century.Patient profiling in diabetes and role of canagliflozin.Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts.Plasma metabolomics reveal alterations of sphingo- and glycerophospholipid levels in non-diabetic carriers of the transcription factor 7-like 2 polymorphism rs7903146 Association of TCF7L2 allelic variations with gastric function, satiation, and GLP-1 levels.The Protective Effect of Transcription Factor 7-Like 2 Risk Allele rs7903146 against Elevated Fasting Plasma Triglyceride in Type 2 Diabetes: A Meta-Analysis.Pancreatic beta-cell function and type 2 diabetes risk: quantify the causal effect using a Mendelian randomization approach based on meta-analyses Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.Interactions between genetic background, insulin resistance and β-cell function.Animal models of GWAS-identified type 2 diabetes genes.Several type 2 diabetes-associated variants in genes annotated to WNT signaling interact with dietary fiber in relation to incidence of type 2 diabetes.The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus.IGF2BP2 rs11705701 polymorphisms are associated with prediabetes in a Chinese population: A population-based case-control study.Pharmacogenetics of oral antidiabetic drugs.Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.Untangling the interplay of genetic and metabolic influences on beta-cell function: Examples of potential therapeutic implications involving TCF7L2 and FFAR1.Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders.Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia.Genetics of type 2 diabetes and potential clinical implications.Phytochemicals targeting genes relevant for type 2 diabetes.Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes.Role of pancreatic transcription factors in maintenance of mature β-cell function.Genetics of drug response in type 2 diabetes.Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: "the earlier, the better".Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.Pharmacogenetics of posttransplant diabetes mellitus.Survival of pancreatic beta cells is partly controlled by a TCF7L2-p53-p53INP1-dependent pathway.TCF7L2 splice variants have distinct effects on beta-cell turnover and function.New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser.

P2860

Q24630735-E9EC9ADC-029C-48C9-9C6A-697E6695DC51 Q26747128-D0636F8F-1321-45E5-A113-A4F084E63D36 Q26996335-EAB9EAE5-789A-4202-A26A-282B140B578B Q27012497-6CEDFD7F-A7F2-47D7-AF4F-1148DE55E2FA Q27027920-7265A87C-67C7-4298-834B-6631F5637F4C Q30248914-F61BAA33-321E-4102-881A-04D8D33B89DC Q31114603-56ED3EBC-1E17-48FF-B737-761F1FE5F87C Q33585692-714228FD-0DD6-4906-9473-24C4992087BA Q33593963-E069B2B6-E758-40D1-B61A-051D1C55A97E Q34017323-2F36FD90-2F1B-42DC-8DDF-9256F58970F1 Q34671155-F6973906-1B01-462A-B492-683D04B5F2E8 Q34729268-4785D75B-0900-4DD5-85FB-B958796487A0 Q34940230-150707DC-EE3D-4849-9EC3-0CA25C7FD3BB Q35036444-4FBE1959-7EB5-41D5-8E91-CD99344D7921 Q35075403-01591290-94AB-4B80-BBE9-BE4A6091188A Q36245431-8068CE90-0659-4A39-A04D-582EFA071A6D Q36714258-07ECC2C7-D515-4E1E-A031-F13CB08EA86C Q36783856-7F8C3289-6F0A-4D6B-B4ED-3AC2B55E5237 Q36790858-6CFC9419-3460-4294-8030-5DCB03253BDF Q36845050-2EEF3375-E2AD-458E-8A96-D40D4C91A1EA Q37142098-34A29D7E-8AF5-4960-A5A6-CA0271C0A7CC Q37150550-B0937088-813C-467B-B763-3130011D81CA Q37204132-F4C2523F-2D41-47E5-9DA0-AA2BE013A479 Q37353476-9B68B436-2BFF-47E5-8DED-CE4B10AE3928 Q37427298-D3BEC0EF-17F0-452B-B5E5-CFB6A12C3CCC Q37702457-58BF71CE-1598-4534-8DBF-96E00F10085C Q37911549-F54FF150-AA71-4958-85DE-6805BFF184FE Q38038655-34300FBE-83C1-41A7-AD0E-6FB3ABE70D1C Q38078821-0316F035-D4F6-4223-B184-0478D1F76FBB Q38112779-B7C86F6D-228E-48C3-BADB-493636FE9E85 Q38180221-D9A718FC-0381-4F44-BF8E-824B02787C92 Q38385473-8EC5CFF6-A7CA-43CF-BDB4-9EE9E6540397 Q38480670-61B9E3D5-ABB7-4F57-BAD5-41A364413A51 Q38557038-7F765001-6D09-4DD9-8236-DDC668D33B50 Q38747416-231790EF-BAB2-4DD3-9032-87EA0A73D899 Q38831752-608FD272-B16C-4A48-9CE9-E913671CF63D Q39204562-98648371-5D9D-4FB9-A68C-31B8868CCDED Q39464436-795B50F8-19A8-4696-BDCC-89AAD057FBF5 Q39584862-02D37B13-62AA-4728-8074-2D8DCF9B0562 Q39626084-37057C51-A2F9-41F1-BA18-8B6A6E47E6F0

P2860

TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

http://www.wikidata.org/entity/Q33604496

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

TCF7L2 variant rs7903146 affec ...... by modulating incretin action.

@ast

TCF7L2 variant rs7903146 affec ...... by modulating incretin action.

@en

type

label

TCF7L2 variant rs7903146 affec ...... by modulating incretin action.

@ast

TCF7L2 variant rs7903146 affec ...... by modulating incretin action.

@en

prefLabel

TCF7L2 variant rs7903146 affec ...... by modulating incretin action.

@ast

TCF7L2 variant rs7903146 affec ...... by modulating incretin action.

@en

P1433

Q33604496-AF552344-54B6-43CB-9417-979ABF294A09

P1476

Q33604496-A345CD25-46F5-47A5-A692-CBB8D8BA744C

P2093

Q33604496-350335D3-EDF2-4D8E-AD37-3494AB446B0B

Q33604496-634FF50B-0258-4596-8C8D-DC3CE77CBA11

Q33604496-991AD441-95A6-4F08-9766-1449A918B127

Q33604496-DFACEED4-6CEB-455A-BD34-7B2E780A2E7A

Q33604496-E404CC6C-86E2-47AB-9BDE-25CCE9613838

Q33604496-EEE47599-C36E-4C8A-AEE5-D100A71F81E1

P2860

Q33604496-046C828B-A6EE-440F-AEF2-ED22FFC5657D

Q33604496-0B387ACE-F1B7-425E-B218-44C07394A17F

Q33604496-1E94C5CE-28FE-4369-A2AB-D47A8623BE73

Q33604496-2025E847-AC15-4B32-A1AF-FCCC13BEE153

Q33604496-22BE0847-03D5-4100-91FA-470F957AB3E9

Q33604496-389FBA95-A587-469F-8D66-80D308FBF7A0

Q33604496-5BCD7207-8B0A-42C9-8958-7289DC6CABFD

Q33604496-6089D854-9E19-4549-8814-F24E86B2D8F2

Q33604496-668C64A2-C887-497D-B937-E362A10D9781

Q33604496-68BF1954-0DD2-48D0-B387-3C1C7FD5852B

P304

Q33604496-7D3146DD-B76D-45D2-AF7B-745B71653973

P31

Q33604496-41A8804E-BD74-4CA8-9EE0-E10D0FAFE40A

P356

Q33604496-A53791BC-0FAF-4745-A47C-70317B1B8B8C

P407

Q33604496-6823FF4E-CD5C-4FF5-8FAF-93D722539727

P433

Q33604496-87E6EFF0-1D12-447F-9115-3470EA0DE83D

P478

Q33604496-A7F8D761-5B59-461C-A20B-0063B4E77632

P50

Q33604496-EACAA3D6-FF5C-45F1-BC02-567D75A0CEEC

P577

Q33604496-88C4EAE2-9178-4A03-B88F-40FCDEDA1458

P5875

Q33604496-D3B50FFC-DF68-44A0-B660-8C4492ACFE3A

P698

Q33604496-1882C900-2425-4054-B309-312BACB5D4EB

P921

Q33604496-2BE0ACB0-727E-4672-83FF-304F496955BA

P932

Q33604496-EE329D70-46AD-4E9A-9315-E67533749E19

P356

P1433

P1476

TCF7L2 variant rs7903146 affec ...... by modulating incretin action

@en

P2093

Burton Wice

http://www.w3.org/2001/XMLSchema#string

Dennis T Villareal

http://www.w3.org/2001/XMLSchema#string

Graeme I Bell

http://www.w3.org/2001/XMLSchema#string

Heather Robertson

http://www.w3.org/2001/XMLSchema#string

Hung Tran

http://www.w3.org/2001/XMLSchema#string

Kenneth S Polonsky

http://www.w3.org/2001/XMLSchema#string

P2860

TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta

Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function

The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus

Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes

Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity.

Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans.

TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.

Association of TCF7L2 gene polymorphisms with reduced acute insulin response in Hispanic Americans.

P304

479-485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB09-1169

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Bruce W Patterson

P577

2009-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40027350

http://www.w3.org/2001/XMLSchema#string

P698

19934000

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2809956

http://www.w3.org/2001/XMLSchema#string